Latest News

 Filter by Provider

FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options.

The market has grossly misjudged this company's long-term prospects.

Bitcoin (CRYPTO: BTC) is down 2% compared to gold sliding 4% after the Federal Reserve delivered hawkish signals, an unusual reversal as Bitcoin typically underperform

Berkshire Hathaway's $373 billion cash pile exceeds the value of 477 of the 500 companies in the S&P 500.

IREN Ltd (NASDAQ:IREN) shares are trading lower on Thursday morning.

Two Brazilian states, Goias and Minas Gerais, known for their abundant reserves of rare earths and lithium, are on the verge of finalizing critical minerals cooperation agreements with the U.S.

Wall Street is nervous about these proven winners. That's often a good sign.

Investors can feel comfortable holding this ETF for the long haul.

Stock futures slightly lower, Alibaba falls after downbeat earnings, other stocks decline in pre-market trading.

GE Aerospace's shares slid over the past month, but fellow industrial giants Caterpillar and Honeywell have gotten of to a stronger start to 2026.

Alibaba stock fell early Thursday after the Chinese tech giant reported fiscal third-quarter revenue below expectations.

Here's some basic guidance to know if you're on track or not.

Boot Barn Holdings, a national leader in western and workwear retail, reported a notable insider sale amid steady operational performance but volatile stock price movements.

Concentrix Corporation will release its Q1 earnings on March 24, with analysts expecting $2.65 per share. Its annual dividend yield is 4.68%.

Cloud computing is a huge business that will profit over the long term from AI.

LNG crisis worsens as Shell reports a security incident at Ras Laffan, Qatar. Staff are safe, but production remains shut down.

Zoom Communications shares rose 0.6% to close at $76.43 on Wednesday, while Citigroup gained 0.9% to settle at $108.67 during the session.

Fast-food chain Arcos Dorados (NYSE:ARCO) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 10.7% year on year to $1.27 billion. Its GAAP pr...